MICA and cancer: Since some cancer patients develop high-titre anti-MICA antibodies that antagonize the suppressive effects of sMICA (59, 60), and the generation of autoantibodies occurs in at least some COVID-19 disease pathologies (61, 62) we also assayed whether the levels of soluble MICA detected might be modulated by anti-MICA antibodies in patients with severe disease, but such antibodies were detected in only a few critically-ill patients (Supplementary Figure 6A) and no correlation between the levels of MICA-reactive autoantibodies and soluble MICA in plasma was observed (Supplementary Figure 6B).